Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, firstname.lastname@example.org
Britain vote to leave the European Union, a historic decision sure to reshape current and future business activities in the biopharmaceutical environment. As a first direct consequence the European Medicines Agency (EMEA), the drug regulator for Europe, which is headquartered in London in new offices, will have to leave the UK and find a new home, in addition the UK will lose a voice at the EU table. Officials in Italy, Sweden and Denmark have already expressed interest in taking EMEA over as a host country.
In the last issue of Biopharmaceutical Newsweek we had indicated that a WHO panel has stated that there was no need to postpone or move the 2016 Olympic Games in Rio de Janeiro (August 5-21). But this week the Games have suffered its highest-profile withdrawal to date as golf's world No. 4 Rory McIlroy (Ireland) announced he wouldn't be competing amid fears surrounding the Zika virus. "After much thought and deliberation, I have decided to withdraw my name from consideration for this summer's Olympic Games in Rio de Janeiro. After speaking with those closest to me, I've come to realize that my health and my family's health comes before anything else. Even though the risk of infection from the Zika virus is considered low, it is a risk nonetheless and a risk I am unwilling to take." McIlroy said in a statement.
Innovio Pharmaceuticals (Plymouth, PA, USA) announced it received FDA approval to initiate a phase 1 trial of its Zika DNA vaccine GLS-5700, which induces robust antibody and T cell responses in animal models. The product is co-developed with GeneOne Life Sciences (Seoul, South Korea) and is produced by VGXI (Houston, Texas). The phase 1 study will test GLS-5700 in 40 healthy subjects using the VGXI DNA delivery system Cellectra, a technology which allows a safer and quicker production than egg or cell-based products.
Scientists from the Imperial College in London now suggest that previous exposure to the dengue virus may increase the potency of Zika infection and that the recent outbreak of Zika may have been driven in part to previous exposure to the dengue virus.
In a letter to its stockholders, Medivation refutes each Sanofi’s solicitation argumentation and urges its shareholders to reject the current bid at $52.50 per share, a rejection recommended by proxy advisory firm Glass, Lewis & Co. The share closed at $56.95 on June 24.
Impax Laboratories (Hayward, CA, USA) acquires a portfolio of 17 generic drugs from Teva Pharmaceuticals for $586 million as a divesture process mandated by the US Federal Trade Commission preconditioning the Allergan’s generic business acquisition by Teva for $40.5 billion.
Celgene (Summit, NJ, USA) invests $50 million in a consortium partnership with four NCI cancer centers: The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai- to access research on new cancer treatments as well as new diagnostics. Each institution will receive $12.5 million over a 10-year collaboration. The four consortium members are among the 69 institutions designated as Cancer Centers by the National Cancer Institute (NCI).
Cell Medica (London, UK) licenses Baylor College of Medicine’s (Houston, Texas) proprietary natural killer T (NKT) cell immunotherapy platform as well as five drug candidates in an extended co-development partnership agreement. The partnership will apply chimeric antigen receptor (CAR) technology to NKT cells as a novel immune cell type with biological properties that may be particularly effective for targeting solid tumors. Financial terms of the deal were not disclosed.
Teva Pharmaceuticals and AstraZeneca settle their litigation about a patent infringement on Byetta or exenatide, allowing Teva to market a generic version of the drug in the US beginning October 1, 2017.
Approval of drugs, vaccines, diagnostics and devices.
The European Commission has approved Gilead’s Odefsey (emtricitabine/rilpivirine/tenofir alafenamide, or TAF) for the treatment of certain patients with HIV-1 infection. Odfesey’s is Gilead’s second TAF-based treatment to receive a European approval. It combines the antiviral efficacy and safety profile of the new Descovy backbone with the established tolerability profile of rilpivirine as a third agent.
US FDA approves OPKO Health’s (Miami, FL, USA) an extended-release capsule of Rayaldee or calcifediol, for the treatment of secondary hyperparathyroidism associated with vitamin D insufficiency in adults with stage 3 to stage 4 chronic kidney disease.
US advisors of the Centers for Disease Control and Prevention (CDR) are advising against the use of AstraZeneca’s FluMist Quadrivalent for the 2016/2017 influenza season, based on data from the last three flu seasons in the US which indicated that FluMist was not effective in children two-to- seventeen years of age.
Drugs at clinical stage
US FDA grants breakthrough status to Incyte’s (Wilmington, Del, USA) Jakafi, or ruxolitinib, for the treatment of acute graft-versus-host disease, a condition where the donated tissue view the recipient’s body as foreign and attack the body. There are no currently approved treatment for the disorder. Jakafi is a JAK1/JAK2 inhibitor, already approved in the US for the treatment of a blood cancer called polycythemia vera and a bone marrow disorder called myelofibrosis.
US FDA grants orphan status to Wave Life Science’s (Cambridge, MA, USA) WVE-1200101 as a treatment of Huntington’s disease. WVE-120101 targets rs362307, a single nucleotide polymorphism associated with the disease-causing mutation in the huntingtin gene.
US FDA grants fast track to Oncternal Therapeutics (San Diego, CA, USA) TK216, a first-in-class small molecule that inhibits the biological activity of ets-family transcription factor oncoproteins, for the treatment of Ewing sarcoma.
GEN-003, a novel immunotherapy for genital herpes has proven effective in a phase 2 clinical trial. The effect of the treatment, given three times lasted for up to one year. GEN-003 is believed to work through a different pathway from most vaccines by recruiting T cells. It may provide relief similar to that available with daily antiviral medications, but with improved convenience and will be tested in combination with antiviral medications.
Science and Technology
IBM has created a Watson Health medical imaging collaboration with more than fifteen health partners to improve personalized health care. Members of the collaborative will use Watson to analyze previously "invisible" unstructured imaging data in combination with data from other sources, including electronic health records, pathology reports and medical journals among others. The goal is to help doctors make personalized care decisions for individual patients as well as build a bank of information that can be of use to larger patient populations.
Cost, Pricing and Market Access
UK National Institute for Health and Care Excellence (NICE):
backs the use of five medicines: Sanofi/Regeneron’s Praluent or alirocumab and Amgen’s Repatha or evolucumab for the treatment of hypercholesterolemia; Novartis’ Zykadai or ceritinib for the treatment of non-small cell lung cancer; Novartis’ Mekinist or trametinib in combination with Tafinlar or dabratenib, for the treatment of BRAF V600 mutation-positive melanoma and AbbVi’e’s Humira or adalimumab for the treatment of patients with moderate to severe hidradenitis suppurativa, a chronic skin disease characterized by clusters of abscesses or subcutaneous boil-like "infections"
…and continues to reject the use of Celgene’s Vidaza for the treatment of acute myeloid leukemia, because of a high degree of uncertainty about Vidaza's (azacitidine) clinical effectiveness relative to current treatments in the target patient population. The incremental cost-effectiveness ratio was calculated to be around £240,000 per QALY, and therefore well outside the bounds of what is normally considered a cost-effective use of NHS resources.
The Paris public prosecutor has started a manslaughter investigation in connection with a phase 1 clinical trial conducted in January 2016, by the CRO Biotrial (Rennes, France), in which one volunteer died and five others were hospitalized after receiving Bial-Portela’s (Sao Mamede de Coronoda, Portugal) BIA 10 274, a CNS investigational drug.
Novartis continues to invest in its biologics and bring “all our biologics manufacturing under one roof” in Schaftenau (Austria). “Thus here in Austrian between Schaftenau and Kundel, between 2010 and the end of the decade, $1 billion will have been invested to support the extension of manufacturing capacity which we know is required for a biologics portfolio” said Carol Lynch Novartis’s head of biopharmaceuticals.
Apple recruits Dr. Stephen Friend, founder of Sage Bionetworks, an open-science non-profit organization, and a former R&D veteran at Merck & Co., to join Apple’s ResearchKit and take on health related projects
BIO Pharm America on September 13-15 in Boston (USA)
7th Innovation Days on October 3-4 in Paris (France)
BIO Europe on November 7-9 in Cologne (Germany)
BIO Latam on November 29-30 in San Juan (Puerto Rico)
Biofit 2016 on November 30-December 1 in Lille (France)
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.